Arrowhead’s RNAi obesity programs head to Phase 2 after encouraging early data

Arrowhead Pharmaceuticals’ gene-silencing obesity therapies have shown early signs of efficacy in a handful of patients, according to interim data. The company said Tuesday that one of its candidates, an RNAi-based product dubbed ARO-INHBE, improved ...